Table 2.
Baseline participant characteristics in included studies
| Study author (year) | Maternal age (years) | Body mass index (kg/m2) | Baseline TSH (mU/L) | Urinary iodine (μg/L) | Gestational age at trial entry (weeks) | |||||
| Intervention arm (LT4) | Control arm | Intervention arm (LT4) | Control arm | Intervention arm (LT4) | Control arm | Intervention arm (LT4) | Control arm | Intervention arm (LT4) | Control | |
| Casey et al 18 (2017) |
27.7±5.7 | 27.3±5.7 | 28.1±6.4 | 28.2±6.4 | 4.5 (95% CI 4.4 to 4.7) |
4.3 (95% CI 4.2 to 4.5) |
199 (95% CI 184 to 238) |
196 (95% CI 172 to 229) |
16.6±3.0 µ | 16.7±3.0 µ |
| Nazarpour et al 20 (2018) |
27.0±5.34 | 26.9±4.74 | 25.8±4.95 | 26.0±4.64 | 3.8 (IQR 2.8–4.8) |
3.6 (IQR 3.1–4.2) |
140 (IQR 89– 219) |
123 (IQR 86– 220) |
11.4±4.1 α | 12.2±4.3 α |
| Lazarus et al 19 (2012) |
30±5.4 | 31±5.3 | Not reported | UK: 3.8 (IQR 1.5–4.7) Turin: 3.1 (IQR 1.3–4.0) |
UK: 3.2 (IQR 1.2–4.2 Turin: 2.4 (IQR 1.3– 3.9) |
Not reported | 12+3
(11+6, 13+6) # |
12+3
(11+6, 13+5) # |
||
Results presented as either means±SD or as median (with IQR or 95% CI) as described, LT4: levothyroxine.
Control, Placebo (Casey et al), no treatment (Nazarpour, Lazarus), µ=at randomisation, α=at first visit, # at screening.
TSH, thyroid stimulating hormone.